Correspondence 0001193125-23-267290 from Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc.
Date: Oct. 31, 2023 · CIK: 0001907108 · Accession: 0001193125-23-267290
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274777
Letter
Lexeo Therapeutics, Inc.
345 Park Avenue South, Floor 6
New York, New York 10010
October 31, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Tim Buchmiller, Jason Drory, Eric Atallah and Lynn Dicker
Re: Lexeo Therapeutics, Inc.
Registration Statement on Form S-1, as amended (File No. 333-274777)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Lexeo Therapeutics, Inc. (the “Company”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-1 (as amended to date, the “Registration Statement”) and declare the Registration Statement effective as of 4:00 p.m. Eastern time, on November 2, 2023, or as soon thereafter as possible, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission.
Once the Registration Statement has been declared effective, please orally confirm that event with Eric Blanchard of Cooley LLP at (212) 479-6565 or, in his absence, Dayne Brown of Cooley LLP at (212) 479-6712.
Under separate cover, you will receive today a letter from the managing underwriters of the proposed offering joining in the Company’s request for acceleration of the effectiveness of the Registration Statement.
* * *
[Signature Page Follows]
Very truly yours,
Lexeo Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Lexeo Therapeutics, Inc. 345 Park Avenue South, Floor 6 New York, New York 10010 October 31, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller, Jason Drory, Eric Atallah and Lynn Dicker Re: Lexeo Therapeutics, Inc. Registration Statement on Form S-1, as amended (File No. 333-274777) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Lexeo Therapeutics, Inc. (the “Company”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-1 (as amended to date, the “Registration Statement”) and declare the Registration Statement effective as of 4:00 p.m. Eastern time, on November 2, 2023, or as soon thereafter as possible, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. Once the Registration Statement has been declared effective, please orally confirm that event with Eric Blanchard of Cooley LLP at (212) 479-6565 or, in his absence, Dayne Brown of Cooley LLP at (212) 479-6712. Under separate cover, you will receive today a letter from the managing underwriters of the proposed offering joining in the Company’s request for acceleration of the effectiveness of the Registration Statement. * * * [Signature Page Follows] Very truly yours, Lexeo Therapeutics, Inc. /s/ R. Nolan Townsend By: R. Nolan Townsend Title: Chief Executive Officer cc: Jenny Robertson, Chief Legal and Administrative Officer, Lexeo Therapeutics, Inc. Eric Blanchard, Cooley LLP Divakar Gupta, Cooley LLP Peter Byrne, Cooley LLP Siavosh Salimi, Paul Hastings LLP William A. Magioncalda, Paul Hastings LLP